Abstract
Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are neurodegenerative diseases, which cause progressive paralysis and premature death in affected adults and children. The treatment rational for these diseases is to halt or delay the degeneration of motor neurons but to date there are no effective drugs. This may however change with recent advances in gene therapy using lentiviral vectors. These vectors can transfer genes to motor neurons with high efficiency and give long term expression. One of these vector systems, based on the equine infectious anaemia virus (EIAV), can insert genes into the cells of the central nervous system after remote delivery including delivery into the muscle by exploiting retrograde transport pathways. This opens up the exciting possibity of rescuing the denervation of key muscle groups in patients by simple injections of these neurotropic lentiviral vectors into the muscle. This review will describe the general features of lentiviral vectors derived from the EIAV. It will then describe some key examples of gene transfer and genetic correction in animal models of motor neuron disease. The prospects for the clinical evaluation of lentiviral vectors for the treatment of human motor neuron disease will be outlined.
Keywords: eiav, motor neuron, motor neuron diseases, als, sma, ientiviral, gene therapy
Current Gene Therapy
Title: Non-Primate EIAV-Based Lentiviral Vectors as Gene Delivery System for Motor Neuron Diseases
Volume: 4 Issue: 3
Author(s): M. Azzouz and N. Mazarakis
Affiliation:
Keywords: eiav, motor neuron, motor neuron diseases, als, sma, ientiviral, gene therapy
Abstract: Motor neuron diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) are neurodegenerative diseases, which cause progressive paralysis and premature death in affected adults and children. The treatment rational for these diseases is to halt or delay the degeneration of motor neurons but to date there are no effective drugs. This may however change with recent advances in gene therapy using lentiviral vectors. These vectors can transfer genes to motor neurons with high efficiency and give long term expression. One of these vector systems, based on the equine infectious anaemia virus (EIAV), can insert genes into the cells of the central nervous system after remote delivery including delivery into the muscle by exploiting retrograde transport pathways. This opens up the exciting possibity of rescuing the denervation of key muscle groups in patients by simple injections of these neurotropic lentiviral vectors into the muscle. This review will describe the general features of lentiviral vectors derived from the EIAV. It will then describe some key examples of gene transfer and genetic correction in animal models of motor neuron disease. The prospects for the clinical evaluation of lentiviral vectors for the treatment of human motor neuron disease will be outlined.
Export Options
About this article
Cite this article as:
Azzouz M. and Mazarakis N., Non-Primate EIAV-Based Lentiviral Vectors as Gene Delivery System for Motor Neuron Diseases, Current Gene Therapy 2004; 4 (3) . https://dx.doi.org/10.2174/1566523043346291
DOI https://dx.doi.org/10.2174/1566523043346291 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Spinal Muscular Atrophy: Molecular Mechanisms
Current Molecular Medicine Neuroprotective Role of Natural Polyphenols
Current Topics in Medicinal Chemistry Estrogen and Cytokines Production - The Possible Cause of Gender Differences in Neurological Diseases
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Neuropharmacology Recent Advancement of Pyrazole Scaffold Based Neuroprotective Agents: A Review
CNS & Neurological Disorders - Drug Targets Natural Triterpenoids and their Derivatives with Pharmacological Activity Against Neurodegenerative Disorders
Mini-Reviews in Organic Chemistry Brain Nitric Oxide and Its Dual Role in Neurodegeneration / Neuroprotection: Understanding Molecular Mechanisms to Devise Drug Approaches
Current Medicinal Chemistry Antioxidant Enzyme Mimics with Synergism
Mini-Reviews in Medicinal Chemistry Current and Future Drugs for Appetite Regulation and Obesity Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Neuroprotection of (+)-2-(1-Hydroxyl-4-Oxocyclohexyl) Ethyl Caffeate Against Hydrogen Peroxide and Lipopolysaccharide Induced Injury via Modulating Arachidonic Acid Network and p38-MAPK Signaling
Current Alzheimer Research Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry Meet Our Associate Editor
Current Molecular Medicine Neuro-Transmitters in the Central Nervous System & their Implication in Learning and Memory Processes
Current Medicinal Chemistry Cyclin-Dependent Kinase 5 (Cdk5): A Potential Therapeutic Target for the Treatment of Neurodegenerative Diseases and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Targeting Exocytosis: Ins and Outs of the Modulation of Quantal Dopamine Release
CNS & Neurological Disorders - Drug Targets Melatonin and Melatonergic Influence on Neuronal Transcription Factors: Implications for the Development of Novel Therapies for Neurodegenerative Disorders
Current Neuropharmacology MicroRNA Dysregulation in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets The Role of Autophagy: What can be Learned from the Genetic Forms of Amyotrophic Lateral Sclerosis
CNS & Neurological Disorders - Drug Targets X-ray Crystallography and Computational Docking for the Detection and Development of Protein–Ligand Interactions
Current Medicinal Chemistry Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets